Clicky

Mirum Pharmaceuticals, Inc.(MIRM) News

Date Title
Apr 2 Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Mar 29 Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
Mar 26 Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares
Mar 25 Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
Mar 15 Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
Mar 13 Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
Jan 16 Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
Jan 15 Should You Invest in Mirum Pharmaceuticals (MIRM)?
Dec 18 Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia
Nov 30 Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
Sep 11 Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer
Sep 9 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 6 Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why
Sep 6 Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
May 1 VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Apr 27 Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
Apr 27 Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release